Jameel Muzaffar

Jul 17, 2024 | mdpi.com | Muhammed Ayas |Rosalyn Parker |David Muir |Jameel Muzaffar

1. IntroductionCochlear implants (CIs) have revolutionised hearing rehabilitation options for individuals with severe to profound hearing loss, offering life-changing access to sound. By bypassing damaged parts of the inner ear, these surgically implanted devices directly stimulate the auditory nerve, enabling recipients to perceive sound [1,2].

Jul 15, 2024 | mdedge.com | Jameel Muzaffar

In this special supplement to Federal Practitioner, Dr. Jameel Muzaffar, MD shares insights into a second-line treatment option for previously treated radioiodine-refractory differentiated thyroid cancer (DTC), along with an exploratory analysis of BRAF mutation status. It discusses the challenges associated with metastatic DTC and the significance of understanding factors like BRAF mutation status in treatment decisions.

Jul 4, 2024 | entandaudiologynews.com | Jameel Muzaffar |Anne GM Schilder |James O’Hara

In a follow-up to the interview with Anne Schilder back in 2016*, Jameel Muzaffar speaks to Anne and to James O’Hara about the current research landscape in ENT in the UK. *Banerjee A. In conversation with Professor Anne Schilder. ENT & Audiology News 2016;24(6):62-3. Jameel Muzaffar, Anne Schilder and James O’Hara. Jameel Muzaffar: Please could you introduce yourselves? Anne Schilder: I am an ENT surgeon at UCLH’s Royal National ENT Hospital and hold a chair at the UCL Ear Institute.

May 10, 2024 | onclive.com | Jameel Muzaffar

May 10, 2024Jameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.